Colorectal cancer
Conditions
Interventions
Observation group:None
Sponsors
Panzhihua Hospital of Integrated Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. All subjects voluntarily participated in the study and signed informed consent; 2. 18 years old =70g/L; b) neutrophil count (ANC) >=1.5×109/L; c) platelet count (PLT) >=75×109/L. (2) Liver function tests should meet the following criteria: a) alanine aminotransferase (ALT) =12 weeks; 8. Patients who had not participated in other clinical trials within 4 weeks before enrollment; 9. Investigator assessment of patients who could use irinotecan hydrochloride liposome injection (II).
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.Presence of a severe active infection? (> Grade 2 CTCAE5.0), or autoimmune disease?; 3.Patients with brain metastases; 4.patients are known to be allergic to any component of the test drug; 5.Patients who have had any cancer other than colorectal cancer prior to the start of the study treatment. Exceptions include cervical carcinoma in situ, cured basal cell carcinoma, and thyroid papillary carcinoma; 6.Severe cardiovascular and cerebrovascular diseases; 7.Vulnerable groups, including people with mental illness, people with cognitive impairment, critically ill patients, minors, pregnant women, etc; 8.The researchers determined that other conditions were not suitable for inclusion in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free Survival;Overall Survival;Objective response rate; | — |
Countries
China
Contacts
Public ContactLei Xiaolin
Panzhihua Hospital of Integrated Chinese and Western Medicine
Outcome results
None listed